ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

A focused discussion on how ADT is used as the backbone of prostate cancer therapy across different prostate cancer risk groups and according to metastatic and castration sensitivity status.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.How PSA Has Impacted the Use of ADT in Prostate Cancer

Now Viewing

EP: 2.ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

EP: 3.Understanding and Mitigating the Cardiometabolic Risks of ADT

EP: 4.Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

January 2023 AbbVie Inc. Company Confidential

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Recent Content

FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer

Urinary bladder cancer with organs and tumors or cancerous cells 3D rendering illustration with male body. Image Credit: © Matthieu - stock.adobe.com

First-line disitamab vedotin plus toripalimab under review in China for la/mUC

BCG/ICI combinations offer potential paradigm shift in BCG-naïve NMIBC

Intravesical gemcitabine/docetaxel formulation shows encouraging efficacy in NMIBC

View More Recent Content

Do not sell my Personnal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

EP: 1.How PSA Has Impacted the Use of ADT in Prostate Cancer

EP: 2.ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer

EP: 3.Understanding and Mitigating the Cardiometabolic Risks of ADT

EP: 4.Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

Newsletter